Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American Society of Hematology (ASH) being one of them.
The 64th ASH Annual Meeting and Exposition is a four-day premier event in malignant and non-malignant hematology, scheduled to start on December 10, 2022. Like every year, the ASH conference shared new abstracts from a robust portfolio and pipeline of advanced therapeutic platforms in cancer and other blood disorders, highlighting the impact of our bold science in research. On this note, Delveinsight has listed a few major abstracts for diffuse large B-cell lymphoma (DLBCL).
The key abstracts have been summarized in the table below:
Drug regimen
|
Abstract ID
|
Abstract Title
|
Trial ID
|
Company
|
Class
|
Tafasitamab + Lenalidomide + R-CHOP
|
2947
|
Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
|
NCT04824092
(frontMIND)
|
MorphoSys AG
|
CD19-directed monoclonal antibody
|
Odronextamab
|
444
|
Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
|
NCT03888105
(ELM-2)
|
Regeneron Pharmaceuticals
|
Bispecific antibody
|
Loncastuximab Tesirine + Rituximab
|
2955
|
A Phase II, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)
|
NCT05144009 (LOTIS-9)
|
ADC Therapeutics
|
Antibody Drug Conjugate (ADC)
|
Epcoritamab + R-DHAX/C
|
443
|
Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase I/II Results
|
NCT04663347
(EPCORE NHL-2)
|
Genmab/AbbVie
|
Bispecific antibody
|
Mosunetuzumab
|
738
|
Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
|
NCT03677154
|
Roche
|
Bispecific antibody
|
Axicabtagene Ciloleucel + Lenzilumab
|
4635
|
ZUMA-19: A Phase I/II Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma
|
NCT04314843 (ZUMA-19)
|
Gilead Sciences
|
CAR-T cell therapy
|
Iberdomide ± Anti-CD20
|
233
|
Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase I/II Study
|
NCT04464798
|
BMS
|
Immunomodulatory imide drug (IMiDs)
|
Tafasitamab + Lenalidomide + R‑CHOP
|
1619
|
First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
|
NCT04134936
(First-MIND)
|
MorphoSys AG
|
CD19-directed monoclonal antibody
|
Glofitamab + R-CHOP
|
737
|
Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
|
NCT03467373
|
Roche
|
Bispecific antibody
|
YTB323
|
439
|
YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
|
NCT03960840
|
Novartis Pharmaceuticals
|
CAR-T cell therapy
|